Archived explainer. For the current picture see today's BLCO page.
Why Is BAUSCH LOMB CORP (BLCO) Stock Up Today?
BAUSCH LOMB CORP (BLCO) is up +15.78% in the latest session. Our newswire has captured 11 stories on BLCO across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Bausch & Lomb Corp (BLCO) shares surged 15.78% to close at $20.40. The primary driver was the company’s third-quarter 2026 earnings report, which showed a swing to profitability and a raise in full-year guidance.
What Happened
The eye-health company reported third-quarter net income of $32 million, or 9 cents a share, compared with a loss of $28 million, or 8 cents a share, in the same period last year. Revenue for the quarter reached $1.375 billion, representing a 7% increase as reported and an 8% increase in constant currency. Management attributed the growth to broad-based performance across all segments, specifically driven by dry eye drugs and premium surgical lenses.
Following the results, Bausch & Lomb raised its 2026 revenue guidance to a range of $5.450 billion to $5.550 billion, up from the previous outlook of $5.440 billion to $5.540 billion. Adjusted EBITDA guidance was also increased to $1.090 billion to $1.140 billion. The company’s adjusted earnings per share of $0.34 exceeded the consensus estimate of $0.22.
What The Data Shows
The stock’s move to $20.40 marks a fresh 52-week high, extending a recent trend that included 37 new 52-week highs. The previous 52-week range was $14.44 to $18.91, meaning the current price sits well above the prior upper bound. Despite the strong quarterly performance, the company remains unprofitable on a trailing twelve-month basis with an EPS of -0.48 and a net margin of -3.2%. The market capitalization stands at $6.3 billion.
Insider activity over the last 90 days shows two sales totaling $1.2 million, with no purchases recorded. The most recent sale was executed by Frederick Munsch, SVP, Controller, and CAO, on August 10, 2026. Andrew C. Von Eschenbach, a director, sold shares on August 6, 2026.
What To Watch
Investors will monitor how the company sustains its Vision '27 momentum and whether the raised 2026 guidance is met. The next scheduled earnings date is not provided in the current data, but coverage breadth remains high with 11 stories from 9 sources in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BLCO by the numbers
The headlines behind the move
Bausch + Lomb raises 2026 guidance to $5.450B-$5.550B revenue and $1.090B-$1.140B adjusted EBITDA as Vision '27 momentum continues
Bausch + Lomb Q3 2026 earnings: revenue rose 8%, margins expanded, and guidance increased again.
Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call October 28, 2026 8:00 AM EDTCompany ParticipantsGeorge Gadkowski - VP & Head of Investor...
Why is Bausch + Lomb stock surging today?
Why is Bausch + Lomb stock surging today?
Bausch + Lomb (BLCO) Q3 2026 Earnings Call Transcript
Dry eye drugs and premium surgical lenses drove broad-based growth across all segments.
Bausch + Lomb Swings to Profit and Lifts Outlook for Year
The eye-health company’s third-quarter net income came in at $32 million, or 9 cents a share, compared with a loss of $28 million, or 8 cents a share, a year earlier.
Bausch + Lomb Lifts 2026 Outlook on Strong Third-Quarter Eye Care Growth
Bausch + Lomb Corporation ( ($BLCO) ) has issued an announcement. Bausch + Lomb reported third-quarter 2026 revenue of $1.375 billion, up 7% as reported and 8% in c...
Bausch Lomb Raises Fy26 Revenue View To 5 450b 5 550b From 5 440b 5 540b
More on BLCO: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BLCO move explainers: 2026-10-29